Grace Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Grace Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q1 2019 to Q1 2024.
  • Grace Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending March 31, 2024 was $47.3M, a 1.33% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $47.3M +$620K +1.33% Mar 31, 2024 10-K 2024-06-21
Q1 2023 $46.7M +$4.26M +10.1% Mar 31, 2023 10-K 2024-06-21
Q1 2022 $42.4M +$3.07M +7.81% Mar 31, 2022 10-K 2023-06-23
Q1 2021 $39.3M +$8.87M +29.1% Mar 31, 2021 10-K 2022-06-21
Q1 2020 $30.5M +$4.5M +17.3% Mar 31, 2020 10-K 2021-06-22
Q1 2019 $26M Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.